Datasheet

MARVELD1 Antibody
CATALOG NUMBER: 5499

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:MARVELD1 antibody can be used for detection of MARVELD1 by Western blot at 1 - 2 μg/mL.

Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1401 - Mouse Heart Tissue Lysate
IMMUNOGEN:MARVELD1 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of human MARVELD1.

The immunogen is located within the first 50 amino acids of MARVELD1.
HOST SPECIES:Rabbit

Properties

PURIFICATION:MARVELD1 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:MARVELD1 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:MARVELD1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:MARVELD1 Antibody: MRVLDC1, MARVEL domain-containing protein 1
ACCESSION NO.:EAW49903
PROTEIN GI NO.:119570288
OFFICIAL SYMBOL:MARVELD1
GENE ID:83742

Background

BACKGROUND:MARVELD1 Antibody: MARVELD1, (MARVEL domain-containing 1), is one of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing proteins. It is a nuclear-localized protein that is widely expressed in normal human tissues. While it has been reported to be overexpressed in colon cancer, MARVELD1 protein levels are generally lower in several primary tumors including ovary, breast, kidney, bladder and liver. This lower level of MARVELD1 expression in tumors is thought to be due to a higher methylation status of the MARVELD1 promoter as treatment of MDA-MB-361 with 5-aza-2'-deoxycytidine restores MARVELD1 expression, suggesting that loss of MARVELD1 expression may contribute to tumorgenicity.
REFERENCES: 1) Wang S, Li Y, Han F, et al. On of MARVELD1, a novel nuclear protein that is down-regulated in multiple cancers and silenced by DNA methylation. Cancer Lett.2009; 282:77-86.
2) Alves PM, Levy N, Stevenson BJ, et al. Identification of tumor-associated antigens by large scale analysis of genes expressed in human colorectal cancer. Cancer Immun.2008; 8:11.
3) Hatada I, Fukasawa M, and Kimura M. Genome-wide profiling of promoter methylation in human. Oncogene2006; 25:3059-64.

For Research Use Only